Translating Research Into a Cure for Type 1 Diabetes Mellitus
Welcome to Orban Biotech:
The Company was founded with the mission of developing and commercializing a novel therapeutic vaccine to treat and prevent Type 1 Diabetes Mellitus (T1DM). The Company's drug is result of the many years of research by Dr. Tihamer Orban and his colleagues at the Joslin Diabetes Center aimed at gaining a better understanding of the immulogical mechanisms underlying T1DM.
The Company's insulin B chain vaccine for T1DM has successfully completed a Phase I clinical trial and the drug is now poised to enter a Phase II clinical trial to evaluate dosing and metabolic effect. The Company's autoantigen based vaccine targets the root cause of T1DM: the loss of self tolerance and the resultant progressive destruction of insulin-producing beta cells. The loss of self tolerance to insulin, a primary autoantigen unleashes autoagressive T cells and initiates the autoimmunity. The insulin B chain vaccine is designed to function by re-establishing self-tolerance towards insulin, thus arresting autoimmune destruction and preserving self-insulin production.
Presently there is no cure or approved treatments for T1DM autoimmunity. T1DM primarily strikes out at children and the autoimmune destruction results in a lifelong dependence on daily injections or infusions of insulin. Those afflicted with T1DM face the challenge of tightly controlling blood sugar to minimize acute and late, often life threatening complications. Dr. Orban's overriding goal has always been to find a cure or therapy for T1DM to help improve the quality of life for children afflicted by this disease. His motto: “with the patients for the patients till the cure”.
.
